Healios K.K. (OTCMKTS:HLOSF – Get Free Report) will likely be announcing its resultson Wednesday, August 12th. Analysts expect the company to post earnings of ($0.0149) per share and revenue of $0.1090 million for the quarter.
Healios K.K. Price Performance
OTCMKTS:HLOSF opened at $1.80 on Wednesday. Healios K.K. has a 12 month low of $1.80 and a 12 month high of $4.45. The company’s 50 day moving average is $1.80 and its 200-day moving average is $2.09.
About Healios K.K.
Healios K.K. is a Tokyo–based biotechnology company focused on the development and commercialization of regenerative medicine products and services. The company’s core expertise lies in induced pluripotent stem cell (iPSC)–derived therapies, with a pipeline that includes retinal pigment epithelium (RPE) cells for age‐related macular degeneration and neural cell products targeting neurological disorders. Healios operates a specialized cell processing center in Chuo‐ku, Tokyo, adhering to stringent quality standards for clinical‐grade cell manufacturing.
Beyond its proprietary programs, Healios provides contract development and manufacturing services (CDMO) to pharmaceutical and research institutions.
See Also
- Five stocks we like better than Healios K.K.
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
Receive News & Ratings for Healios K.K. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healios K.K. and related companies with MarketBeat.com's FREE daily email newsletter.
